$24.46
5.49% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET

Pacira Pharmaceuticals, Inc. Stock price

$24.46
+0.39 1.62% 1M
+1.25 5.39% 6M
-1.42 5.49% YTD
+6.13 33.44% 1Y
-14.15 36.65% 3Y
-34.85 58.76% 5Y
-51.17 67.66% 10Y
+17.44 248.43% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-1.42 5.49%

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$1.2b
Net debt
$130.4m
Cash
$246.3m
Shares outstanding
43.0m
Valuation (TTM | estimate)
P/E
52.0 | 8.1
P/S
1.5 | 1.4
EV/Sales
1.7 | 1.6
EV/FCF
9.5
P/B
1.5
Financial Health
Equity Ratio
50.1%
Return on Equity
-12.8%
ROCE
5.3%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$716.8m | $744.7m
EBITDA
$120.9m | $208.5m
EBIT
$63.6m | $184.4m
Net Income
$21.4m | $129.9m
Free Cash Flow
$124.2m
Growth (TTM | estimate)
Revenue
-16.9% | 6.2%
EBITDA
-35.9% | 30.9%
EBIT
-45.7% | 80.7%
Net Income
126.2% | 230.5%
Free Cash Flow
-35.8%
Margin (TTM | estimate)
Gross
79.2%
EBITDA
16.9% | 28.0%
EBIT
8.9%
Net
3.0% | 17.4%
Free Cash Flow
17.3%
More
EPS
$0.5
FCF per Share
$2.9
Short interest
25.0%
Employees
789
Rev per Employee
$890.0k
Show more

Is Pacira Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Pacira Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

9x Buy
69%
3x Hold
23%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Pacira Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
717 717
17% 17%
100%
- Direct Costs 149 149
34% 34%
21%
567 567
11% 11%
79%
- Selling and Administrative Expenses 347 347
2% 2%
48%
- Research and Development Expense 101 101
6% 6%
14%
121 121
36% 36%
17%
- Depreciation and Amortization 57 57
20% 20%
8%
EBIT (Operating Income) EBIT 64 64
46% 46%
9%
Net Profit 21 21
126% 126%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Pacira Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacira Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material induc...
Neutral
GlobeNewsWire
about one month ago
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District ...
Neutral
GlobeNewsWire
about 2 months ago
BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 18t...
More Pacira Pharmaceuticals, Inc. News

Company Profile

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head office United States
CEO Frank Lee
Employees 789
Founded 2006
Website www.pacira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today